Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.75 |
| ▸ | KDR | P35968 | 2/20 | 0.75 |
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 1/20 | 0.75 |
| ▸ | INSR | P06213 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | FLT4 | P35916 | 1/20 | 0.75 |
| ▸ | CLK1 | P49759 | 1/20 | 0.75 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.75 |
| ▸ | TEK | Q02763 | 1/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.75 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26162 | 1.00 | EGFR (0.75) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL29365524 | 1.00 | EGFR (0.75) | EGFRKDRFBP1ERBB2AURKA | |
| Hydrochloric Acid SCHEMBL641807 | 0.99 | EGFR (0.74) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL19006857 | 0.96 | EGFR (0.75) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL16212621 | 0.93 | EGFR (0.65) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL16212087 | 0.90 | FBP1 (0.76) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL642350 | 0.90 | EGFR (0.64) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL19293607 | 0.89 | FBP1 (0.66) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL17538495 | 0.89 | EGFR (0.63) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL16212227 | 0.89 | FBP1 (0.59) | EGFRKDRFBP1ERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-115304587-A | Preparation method of afatinib impurity | 北京康派森医药科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| US-12435045-B2 | Tyrosine kinase inhibitors and pharmaceutical application thereof | JIANGSU CONCORD BIOTECHNOLOGY CO., LTD (CN) | 2025-10-07 | — | — | US | disclosed |
| CN-119970743-A | Pharmaceutical use of tyrosine kinase inhibitors | 江苏康可得生物技术股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-114394942-B | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-110078718-B | Preparation method of afatinib degradation cyclization impurity | 鲁南制药集团股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115304587-A | Preparation method of afatinib impurity | 北京康派森医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-115304587-A | Preparation method of afatinib impurity | 北京康派森医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-115304587-A | Preparation method of afatinib impurity | 北京康派森医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-113121512-B | Preparation method of quinazolinyl butene amide compound | 江苏晶立信医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022184119-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL USE THEREOF | 江苏康可得生物技术股份有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-114394942-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435045-B2 | Tyrosine kinase inhibitors and pharmaceutical application thereof | SRC, ABL1, ERBB2 | EGFR 9/4885KDR 315/4885FBP1 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.